<tei xml:space="preserve">
    <teiHeader>
        <fileDesc xml:id="_0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl>

        References<lb/> 
        <bibl><label>1</label>. Okubo K, Kurono Y, Ichimura K, Enomoto T, Okamoto Y, Kawauchi H, et al.<lb/> Japanese guidelines for allergic rhinitis 2020. Allergol Int 2020;69:331e45.<lb/> </bibl>
        <bibl><label>2</label>. Matsabura A, Sakashita M, Gotoh M, Kawashima K, Matsuoka B, Kondou S, et al.<lb/> [National epidemiological survey of nasal allergies 2019 (Comparison with<lb/> 1998, 2008): breaking news-for otolaryngologists and their families]. Nippon<lb/> Jibiinkoka Gakkai Kaiho Tokyo 2020;123:485e90 (in Japanese).<lb/> </bibl>
        <bibl><label>3</label>. Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, et al.<lb/> Economic impact of workplace productivity losses due to allergic rhinitis<lb/> compared with select medical conditions in the United States from an<lb/> employer perspective. Curr Med Res Opin 2006;22:1203e10.<lb/> </bibl>
        <bibl><label>4</label>. Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, et al.<lb/> Impact of rhinitis on work productivity: a systematic review. J Allergy Clin<lb/> Immunol Pract 2018;6:1274e86.<lb/> </bibl>
        <bibl><label>5</label>. Cardell LO, Olsson P, Andersson M, Welin KO, Svensson J, Tennvall GR, et al.<lb/> TOTALL: high cost of allergic rhinitis-a national Swedish population-based<lb/> questionnaire study. NPJ Prim Care Respir Med 2016;26:15082.<lb/> </bibl>
        <bibl><label>6</label>. Halmai LA, Neilson AR, Kilonzo M. Economic evaluation of interventions for the<lb/> treatment of asthma in children: a systematic review. Pediatr Allergy Immunol<lb/> 2020;31:150e7.<lb/> </bibl>
        <bibl><label>7</label>. Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A. Economic evaluation of SQ-<lb/>standardized grass allergy immunotherapy tablet (Grazax) in children. Clin-<lb/>icoecon Outcomes Res 2014;6:187e96.<lb/> </bibl>
        <bibl><label>8</label>. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic<lb/> quality-of-life instruments. Pharmacoeconomics 2000;17:13e35.<lb/> </bibl>
        <bibl><label>9</label>. Owen L, Pennigton B, Fischer A, Jeong K. The cost-effectiveness of public health<lb/> interventions examined by NICE from 2011 to 2016. J Public Health (Oxf)<lb/> 2018;40:557e66.<lb/> </bibl>
        <bibl><label>10</label>. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey<lb/> on willingness-to-pay (WTP) for one additional QALY gained: what is the<lb/> threshold of cost effectiveness? Health Econ 2010;19:422e37.<lb/> </bibl>
        <bibl><label>11</label>. Poole CD, Bannister CA, Andreasen JN, Andersen JS, Currie CJ. Estimation of<lb/> health-related utility (EQ-5D index) in subjects with seasonal allergic rhino-<lb/>conjunctivitis to evaluate health gain associated with sublingual grass allergen<lb/> immunotherapy. Health Qual Life Outcomes 2014;12:99.<lb/> </bibl>
        <bibl><label>12</label>. Mukuria C, Rowen D, Harnan S, Rawdin A, Wong R, Ara R, et al. An updated<lb/> systematic review of studies mapping (or cross-walking) measures of health-<lb/>related quality of life to generic preference-based measures to generate util-<lb/>ity values. Appl Health Econ Health Policy 2019;17:295e313.<lb/> </bibl>
        <bibl><label>13</label>. Tuchiya A, Ikeda S, Ikegami N, Nishmura S, Sakai I, Fukuda T, et al. Esti-<lb/>mating an EQ-5D population value set: the case of Japan. Health Econ<lb/> 2002;11:341e53.<lb/> </bibl>
        <bibl><label>14</label>. Monden A, Ogino S. [The evaluation of the utility values for allergic rhinitis<lb/> using EQ-5D]. [J Jap Soc Immunol Allergy Otorhinolaryngol] 2005;23:15e8 (in<lb/> Japanese).<lb/> </bibl>
        <bibl><label>15</label>. Green W, Kleine-Tebbe J, Klimek L, Hahn-Pedersen J, Andreasen JN, Taylor.<lb/> Cost-effectiveness of SQR HDM SLIT-tablet in addition to pharmacotherapy for<lb/> the treatment of house dust mite allergic rhinitis in Germany. Clinicoecon<lb/> Outcomes Res 2017;9:77e84.<lb/> </bibl>
        <bibl><label>16</label>. Dick K, Briggs A, Ohsfeldt R, Grand TS, Buchs S. A quality-of-life mapping<lb/> fuction developed from a grass pollen sublingual immunotherapy trial to a tree<lb/> pollen sublingual immunotherapy trial. J Med Econ 2020;23:64e9.<lb/> </bibl>
        <bibl><label>17</label>. Yu ST, Chang HY, Yao KP, Lin YH, Hurng BS. Validity of EQ-5D in general<lb/> population of Taiwan: results of the 2009 National Health Interview and Drug<lb/> Abuse Survey in Taiwan. Qual Life Res 2015;24:2541e8.<lb/> </bibl>
        <bibl><label>18</label>. Caimmi D, Calderon MA, Bousquet M, Demoly P. Allergen immunotherapy<lb/> outcomes and unmet needs: a critical review. Immunol Allergy Clin North Am<lb/> 2016;36:181e9.<lb/> </bibl>
        <bibl><label>19</label>. Okubo K, Okano M, Sato N, Tamaki Y, Suzuki H, Uddin A, et al. Add-on oma-<lb/>lizumab for inadequately controlled severe pollinosis despite standard-of-care:<lb/> a randomized study. J Allergy Clin Immunol Pract 2020;8:3130e40.<lb/> </bibl>
        <bibl><label>20</label>. Dick K, Briggs A, Brandi H. Application of a mapping function to estimate<lb/> utilities for ragweed allergen immunotherapy trials. Pharmacoecon Open<lb/> 2020;4:649e55.<lb/> </bibl>
        <bibl><label>21</label>. Petou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Fround R, et al. The<lb/> MAPS reporting statement for studies mapping onto generic preference-based<lb/> outcome measures: explanation and elaboration. Pharmacoeconomics 2015;33:<lb/> 993e1011.<lb/> </bibl>
        <bibl><label>22</label>. Okamoto Y, Okubo K, Yonekura S, Hashiguchi K, Goto M, Otsuka T, et al.<lb/> Efficacy and safety of sublingual immunotherapy for two seasons in pa-<lb/>tients with Japanese cedar pollinosis. Int Arch Allergy Immunol 2015;166:<lb/> 177e88.<lb/> </bibl>
        <bibl><label>23</label>. Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, et al. Comparison of<lb/> value set based on DCE and/or TTO data: Scoring for EQ-5D-5L health states in<lb/> Japan. Value Health 2016;19:648e54.<lb/> </bibl>
        <bibl><label>24</label>. Osada T, Okano M. Japanese cedar/cypress pollinosis updated: new allergen,<lb/> cross-reactivity, and treatment. Allergol Int 2021;70:281e90.<lb/> </bibl>
        <bibl><label>25</label>. Kamae I, Thwaites R, Hamada A, Fernandez JL. Health technology assessment in<lb/> Japan: a work in progress. J Med Econ 2020;23:317e22.<lb/> </bibl>
        <bibl><label>26</label>. Shiroiwa T. Cost-effectiveness evaluation for pricing medicines and devices: a<lb/> new value-based price adjustment system in Japan. Int J Technol Assess Health<lb/> Care 2020;36:270e6.<lb/> </bibl>
        <bibl><label>27</label>. Kishikawa R, Koto E. Effect of climate change on allergenic airborne pollen in<lb/> Japan. Immunol Allergy Clin N Am 2021;41:111e25.<lb/> </bibl>
        <bibl><label>28</label>. Tamayama K, Kondo M, Shono A, Okubo I. Utility weights for allergic rhinitis<lb/> based on a community survey with a time trade-off technique in Japan. Allergol<lb/> Int 2009;58:201e7.<lb/> </bibl>
        <bibl><label>29</label>. Canonica GW, Poulsen PB, Vestenbeak U. Cost-effectiveness of Grazax for<lb/> prevention of grass pollen induced rhinoconjunctivitis in Southern Europe.<lb/> Respir Med 2007;101:1885e94.<lb/> </bibl>
        <bibl><label>30</label>. Bachert C, Vestenbeak U, Christensen J, Griffiths UK, Poulsen PB. Cost-effec-<lb/>tiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal<lb/> allergic rhinoconjunctivitis e a Northern European perspective. Clin Exp Allergy<lb/> 2007;37:772e9.<lb/> </bibl>
        <bibl><label>31</label>. Penagos M, Durham SR. Duration of allergen immunotherapy for inhalant al-<lb/>lergy. Curr Opin Allergy Clin Immunol 2019;19:594e605.<lb/> </bibl>
        <bibl><label>32</label>. Yonekura S, Gotoh M, Kaneko S, Maekawa Y, Okubo K, Okamoto Y. Disease-<lb/>modifying effect of Japanese cedar pollen sublingual immunotherapy tablets.<lb/> J Allergy Clin Immunol Pract 2021;9:4103e16.e14.<lb/> </bibl>
        <bibl><label>33</label>. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of<lb/> timothy grass allergen immunotherapy tablets in North American children and<lb/> adolescents. J Allergy Clin Immunol 2011;127:64e71.<lb/> </bibl>
        <bibl><label>34</label>. Fujii T, Ogino S, Arimoto H, Irifune M, Iwata N, Ookawachi I, et al. [Quality<lb/> of life in patients with Japanese cedar pollinosis: using the SF-8 health<lb/> status questionnaire (Japanese version)]. Arerugi 2006;55:1288e94 (in<lb/> Japanese).<lb/> </bibl>
        <bibl><label>35</label>. Gotoh M, Yonekura S, Imai T, Kaneko S, Hirokawa E, Konno A, et al. Long-term<lb/> efficacy and dose-finding trial of Japanese cedar pollen sublingual immuno-<lb/>therapy tablet. J Allergy Clin Immunol Pract 2019;7:1787e97.</bibl>
        </listBibl>
    </text>
</tei>

